Hub : Traits :

Miserableness

735 significantly associated models · 98 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	23453834	24924438	1	1	2.5e-09	6.9e-10	1.0e+00	100	UBXN2A
2	3	48335857	51043528	25	7	3.3e-15	1.0e-10	NaN	NaN	GPX1 MST1R RBM6 RNF123 UBA7
3	3	135806811	136715468	1	1	2.3e-08	1.9e-08	2.5e-01	96	STAG1
4	7	1580921	2977732	1	1	6.4e-09	4.8e-11	3.9e-05	61	FTSJ2
5	7	7429560	8007509	1	1	2.7e-07	1.5e-06	2.8e-02	79	RPA3
6	7	11553163	12967449	1	1	4.5e-08	2.1e-08	1.0e+00	100	TMEM106B
7	8	8092025	12966739	21	1	6.8e-12	1.6e-11	3.6e-03	81	ERI1
8	9	95502571	96898436	1	1	5.0e-08	9.1e-08	1.0e+00	100	RP11-165J3.6
9	11	46010847	48559571	14	7	1.5e-14	9.2e-13	NaN	NaN	ARFGAP2 ARHGAP1 DDB2 FNBP4 MADD NR1H3
10	11	112135760	113952419	4	2	1.6e-12	1.8e-12	1.0e+00	100	DRD2 NCAM1
11	12	109744235	110284465	2	1	9.7e-08	2.3e-07	9.0e-03	75	MVK
12	13	31078511	32595740	1	1	8.7e-08	5.1e-06	4.3e-01	97	B3GALTL
13	17	1805677	3287175	1	1	8.7e-09	5.8e-12	1.3e-04	69	PAFAH1B1
14	17	15214608	16908991	3	1	7.1e-09	4.3e-08	8.6e-01	100	PIGL
15	17	42774693	45796313	19	1	4.3e-11	3.3e-09	7.7e-01	100	MAPT
16	18	52209411	54028036	1	1	1.4e-07	1.5e-07	1.5e-01	92	TCF4

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Depressed Affect (Nagel 2018)	15.90	25	17	37.8	0.99	3.4e-24	ARFGAP2 ARHGAP1 B3GALTL DDB2 DRD2 FNBP4 FTSJ2 GPX1 MADD MAPT MST1R MVK NCAM1 NR1H3 PAFAH1B1 PIGL RBM6 RNF123 RP11-165J3.6 RPA3 STAG1 TCF4 TMEM106B UBA7 UBXN2A
Neuroticism score	14.58	22	13	28.9	0.98	3.3e-17	ARHGAP1 B3GALTL DDB2 DRD2 ERI1 FNBP4 FTSJ2 GPX1 MADD MAPT MST1R MVK NCAM1 NR1H3 PAFAH1B1 RBM6 RP11-165J3.6 STAG1 TCF4 TMEM106B UBA7 UBXN2A
Mood swings	13.72	16	10	22.2	0.99	1.1e-13	DRD2 ERI1 FNBP4 GPX1 MADD MAPT MST1R NCAM1 NR1H3 PIGL RBM6 RP11-165J3.6 STAG1 TCF4 TMEM106B UBA7
Neuroticism (Nagel 2018)	13.25	20	15	33.3	0.98	1.7e-14	ARFGAP2 ARHGAP1 B3GALTL DDB2 DRD2 FNBP4 FTSJ2 GPX1 MADD MAPT MVK NCAM1 NR1H3 PAFAH1B1 RP11-165J3.6 RPA3 STAG1 TCF4 TMEM106B UBXN2A
Neuroticism	13.23	23	17	37.8	0.98	2.0e-17	ARFGAP2 ARHGAP1 B3GALTL DDB2 DRD2 FNBP4 FTSJ2 GPX1 MADD MAPT MST1R MVK NCAM1 NR1H3 PAFAH1B1 RBM6 RP11-165J3.6 RPA3 STAG1 TCF4 TMEM106B UBA7 UBXN2A
Fed-up feelings	12.22	18	8	17.8	0.99	5.7e-17	ARFGAP2 ARHGAP1 B3GALTL DDB2 DRD2 ERI1 GPX1 MADD MAPT MST1R NCAM1 NR1H3 PAFAH1B1 RBM6 RPA3 STAG1 UBA7 UBXN2A
Frequency of tenseness / restlessness in last 2 weeks	9.40	11	3	6.7	0.98	2.2e-07	B3GALTL DRD2 GPX1 MADD MAPT MST1R MVK RNF123 RP11-165J3.6 STAG1 TMEM106B
Neuroticism (2016)	9.06	7	2	4.4	0.97	1.9e-04	DRD2 ERI1 FNBP4 GPX1 MADD MAPT TCF4
Frequency of depressed mood in last 2 weeks	8.75	9	1	2.2	0.98	3.9e-06	DRD2 ERI1 MADD MAPT NCAM1 RP11-165J3.6 STAG1 TMEM106B UBXN2A
Guilty feelings	8.72	8	3	6.7	0.97	7.5e-05	DRD2 ERI1 FNBP4 MADD MAPT NCAM1 PAFAH1B1 UBXN2A
Qualifications: College or University degree	8.53	8	6	13.3	-0.97	3.1e-06	B3GALTL FTSJ2 GPX1 MAPT MST1R RBM6 RNF123 UBA7
Overall health rating	8.34	7	5	11.1	0.99	7.8e-07	GPX1 MST1R NCAM1 RBM6 RNF123 RP11-165J3.6 UBA7
Body mass index (BMI)	8.29	10	9	20.0	0.43	1.6e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 RNF123 STAG1 UBA7
Depression (Nagel 2018)	7.70	8	2	4.4	0.98	3.7e-05	FTSJ2 MADD MAPT NCAM1 RP11-165J3.6 STAG1 TMEM106B UBXN2A
Worry (Nagel 2018)	7.66	11	6	13.3	0.99	3.1e-10	B3GALTL DRD2 FNBP4 MADD MAPT MVK NCAM1 NR1H3 RP11-165J3.6 STAG1 TMEM106B
Qualifications: A levels/AS levels or equivalent	7.65	6	4	8.9	-0.99	4.3e-06	GPX1 MAPT MST1R RBM6 RNF123 UBA7
Leg fat mass (left)	7.60	9	7	15.6	0.44	1.8e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 RNF123 UBA7
Loneliness, isolation	7.52	6	2	4.4	0.99	4.5e-05	FNBP4 GPX1 MADD MAPT STAG1 TMEM106B
Frequency of unenthusiasm / disinterest in last 2 weeks	7.48	3	0	0.0	0.00	1.0e+00	DRD2 STAG1 UBXN2A
Leg fat mass (right)	7.44	9	7	15.6	0.45	1.7e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 RNF123 UBA7
Frequency of tiredness / lethargy in last 2 weeks	7.29	8	3	6.7	0.99	5.9e-06	ARHGAP1 GPX1 MVK PAFAH1B1 RNF123 RP11-165J3.6 STAG1 UBXN2A
Age at First Birth	7.16	5	4	8.9	-0.99	1.9e-05	GPX1 MST1R RBM6 RNF123 UBA7
Taking other prescription medications	7.16	4	3	6.7	0.98	4.7e-04	GPX1 MST1R RBM6 UBA7
Leg fat percentage (left)	7.15	7	6	13.3	0.41	2.7e-01	ERI1 FNBP4 GPX1 MADD MST1R RBM6 UBA7
Leg fat percentage (right)	7.08	7	6	13.3	0.57	1.1e-01	FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Age at first live birth	7.03	5	4	8.9	-0.99	9.8e-06	GPX1 MST1R RBM6 RNF123 UBA7
Heel T-Score	7.00	10	10	22.2	-0.40	1.8e-01	ARFGAP2 ARHGAP1 DDB2 MADD MAPT MST1R NR1H3 RBM6 RNF123 UBA7
Age at last live birth	6.98	5	4	8.9	-0.99	1.0e-05	GPX1 MST1R RBM6 RNF123 UBA7
Worrier / anxious feelings	6.94	6	4	8.9	0.98	8.3e-04	B3GALTL ERI1 MAPT RP11-165J3.6 STAG1 TCF4
Arm fat mass (left)	6.91	9	7	15.6	0.35	2.9e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 RNF123 UBA7
Heel bone mineral density (BMD) T-score, automated (right)	6.89	7	4	8.9	-0.51	1.6e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MST1R NR1H3 RBM6
BMI	6.88	9	7	15.6	0.53	9.7e-02	FNBP4 FTSJ2 GPX1 MADD MST1R MVK RBM6 RNF123 UBA7
Arm fat mass (right)	6.87	8	7	15.6	0.35	3.3e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Arm fat percentage (left)	6.75	8	8	17.8	0.24	5.0e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Heel bone mineral density (BMD) T-score, automated (left)	6.67	7	4	8.9	-0.36	3.4e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MST1R RBM6 UBA7
Seen doctor (GP) for nerves, anxiety, tension or depression	6.62	6	3	6.7	0.97	1.7e-03	B3GALTL DRD2 FTSJ2 GPX1 TCF4 TMEM106B
Arm fat percentage (right)	6.54	8	7	15.6	0.26	4.8e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Suffer from 'nerves'	6.51	6	2	4.4	0.98	5.9e-04	ARHGAP1 ERI1 FNBP4 MADD MAPT NR1H3
Intelligence (Savage-Jansen 2018)	6.50	8	6	13.3	-0.98	3.7e-07	GPX1 MAPT MST1R NCAM1 RBM6 RNF123 STAG1 UBA7
Sensitivity / hurt feelings	6.47	7	4	8.9	0.97	3.5e-04	DRD2 ERI1 MAPT MVK NCAM1 RP11-165J3.6 STAG1
Whole body fat mass	6.43	8	6	13.3	0.38	2.8e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Number of treatments/medications taken	6.39	7	3	6.7	0.98	3.7e-06	B3GALTL FTSJ2 GPX1 MST1R RBM6 RNF123 UBA7
Alcohol intake frequency.	6.29	8	6	13.3	0.35	3.2e-01	DRD2 FNBP4 MADD MAPT MST1R RBM6 TCF4 UBA7
Irritability	6.15	8	3	6.7	0.96	1.7e-04	DRD2 ERI1 FTSJ2 GPX1 MAPT PAFAH1B1 TCF4 TMEM106B
Body fat percentage	6.14	7	6	13.3	0.43	2.5e-01	FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 UBA7
Nervous feelings	5.82	5	3	6.7	1.00	2.7e-04	ERI1 MADD MAPT NR1H3 STAG1
Fluid intelligence score	5.79	6	4	8.9	-0.97	6.4e-05	GPX1 MAPT MST1R RBM6 STAG1 UBA7
Wheeze or whistling in the chest in last year	5.68	6	3	6.7	0.97	6.6e-05	GPX1 MST1R RBM6 RNF123 RP11-165J3.6 UBA7
Alcohol intake versus 10 years previously	5.58	4	3	6.7	1.00	3.7e-05	FTSJ2 MST1R RBM6 UBA7
Tense / 'highly strung'	5.47	4	3	6.7	-0.61	3.9e-01	DRD2 ERI1 RP11-165J3.6 TMEM106B
Trunk fat mass	5.46	7	5	11.1	0.29	4.5e-01	FNBP4 GPX1 MADD MAPT MST1R RBM6 UBA7
Trunk fat percentage	5.40	8	6	13.3	0.21	5.7e-01	FNBP4 FTSJ2 GPX1 MADD MAPT MST1R RBM6 UBA7
Waist circumference	5.40	6	5	11.1	0.47	2.4e-01	FNBP4 FTSJ2 MADD MST1R RBM6 UBA7
Verbal and Numeric Reasoning (VNR)	5.37	8	4	8.9	-0.98	3.4e-07	GPX1 MAPT MST1R NCAM1 RBM6 RNF123 STAG1 UBA7
Qualifications: None of the above	5.37	6	4	8.9	0.99	1.6e-06	B3GALTL GPX1 MST1R RBM6 RNF123 UBA7
Impedance of arm (left)	5.34	9	8	17.8	-0.72	1.2e-02	ERI1 GPX1 MAPT MST1R RBM6 RNF123 STAG1 UBA7 UBXN2A
HDL Cholesterol	5.30	7	1	2.2	-0.72	2.9e-02	ARFGAP2 ARHGAP1 DDB2 MST1R MVK NR1H3 RBM6
Impedance of arm (right)	5.29	10	8	17.8	-0.73	6.7e-03	ERI1 GPX1 MAPT MST1R RBM6 RNF123 STAG1 TMEM106B UBA7 UBXN2A
Average weekly beer plus cider intake	5.22	4	1	2.2	1.00	1.1e-04	ERI1 MST1R RBM6 UBA7
Weight	5.08	8	6	13.3	0.45	1.9e-01	ERI1 FNBP4 GPX1 MADD MST1R RBM6 RNF123 UBA7
Systolic Blood Pressure	5.03	11	8	17.8	0.68	1.6e-02	ARFGAP2 ARHGAP1 DDB2 FNBP4 GPX1 MADD MAPT MVK NR1H3 PAFAH1B1 UBA7
Ever highly irritable/argumentative for 2 days	4.86	2	0	0.0	1.00	1.7e-05	MST1R RBM6
Major Depression (MDD)	4.85	3	0	0.0	0.00	1.0e+00	GPX1 TCF4 TMEM106B
Worry too long after embarrassment	4.80	5	3	6.7	0.99	9.8e-04	DRD2 ERI1 MAPT NCAM1 STAG1
Pain experienced in last month	4.75	3	1	2.2	-1.00	5.5e-04	GPX1 RBM6 UBA7
Ever unenthusiastic/disinterested for a whole week	4.74	2	0	0.0	0.00	1.0e+00	MAPT RNF123
Impedance of whole body	4.73	10	9	20.0	-0.65	2.3e-02	ERI1 GPX1 MAPT MST1R MVK RBM6 RNF123 STAG1 UBA7 UBXN2A
Fasting Glucose	4.55	3	2	4.4	0.00	1.0e+00	FNBP4 MADD NR1H3
Hearing difficulty/problems with background noise	4.51	5	0	0.0	1.00	1.8e-05	ARFGAP2 ARHGAP1 DDB2 MAPT PAFAH1B1
Mean time to correctly identify matches	4.39	3	3	6.7	-1.00	3.2e-03	ARFGAP2 ARHGAP1 DDB2
Number of self-reported non-cancer illnesses	4.39	2	1	2.2	0.00	1.0e+00	FTSJ2 TMEM106B
High blood pressure	4.36	7	4	8.9	0.63	9.7e-02	ARFGAP2 ARHGAP1 DDB2 ERI1 FNBP4 MADD NR1H3
Health satisfaction	4.33	2	0	0.0	0.00	1.0e+00	DRD2 UBA7
Mouth/teeth dental problems: Dentures	4.30	5	1	2.2	0.99	7.3e-06	GPX1 MST1R RBM6 STAG1 UBA7
Financial situation satisfaction	4.25	2	1	2.2	0.00	1.0e+00	GPX1 UBA7
Diastolic blood pressure, automated reading	4.21	9	5	11.1	0.68	2.2e-02	ERI1 FNBP4 GPX1 MADD MST1R NR1H3 PAFAH1B1 RBM6 UBA7
Ever depressed for a whole week	4.16	2	0	0.0	0.00	1.0e+00	MAPT RNF123
Systolic blood pressure, automated reading	4.04	9	5	11.1	0.54	1.4e-01	DDB2 ERI1 FNBP4 GPX1 MADD MAPT NR1H3 PAFAH1B1 UBA7
Hypertension (Self-reported)	4.01	7	2	4.4	0.61	1.1e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 FNBP4 MADD NR1H3
Reaction Time	3.99	3	2	4.4	-1.00	2.1e-03	ARFGAP2 ARHGAP1 DDB2
Chronic bronchitis/emphysema (mother)	3.94	1	0	0.0	0.00	1.0e+00	RBM6
Vascular/heart problems diagnosed by doctor	3.94	6	2	4.4	-0.62	1.3e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MADD NR1H3
Medication: Paracetamol	3.93	4	2	4.4	0.39	6.1e-01	GPX1 MAPT RNF123 UBXN2A
Medication: Co-codamol	3.89	3	0	0.0	1.00	4.0e-04	MST1R RBM6 UBA7
Arm predicted mass (left)	3.86	7	7	15.6	0.72	2.8e-02	ERI1 GPX1 MST1R RBM6 RNF123 UBA7 UBXN2A
Medication: Paracetamol	3.85	4	1	2.2	0.32	6.8e-01	GPX1 MAPT RNF123 UBXN2A
Arm fat-free mass (left)	3.84	7	6	13.3	0.72	2.8e-02	ERI1 GPX1 MST1R RBM6 RNF123 UBA7 UBXN2A
Schizophrenia vs Biploar Disorder	3.82	2	0	0.0	0.00	1.0e+00	MST1R RBM6
Forced expiratory volume in 1-second (FEV1), Best measure	3.77	7	2	4.4	-0.36	4.3e-01	ERI1 FNBP4 GPX1 MAPT RNF123 UBA7 UBXN2A
Hip circumference	3.76	9	6	13.3	0.37	2.6e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MST1R RBM6 RNF123 UBA7
Exposure to tobacco smoke outside home	3.76	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Chest pain or discomfort	3.76	1	0	0.0	0.00	1.0e+00	RNF123
Arm predicted mass (right)	3.75	7	6	13.3	0.71	3.3e-02	ERI1 GPX1 MST1R RBM6 RNF123 UBA7 UBXN2A
Exposure to tobacco smoke at home	3.74	3	1	2.2	0.00	1.0e+00	RBM6 RNF123 UBA7
Forced vital capacity (FVC), Best measure	3.70	7	2	4.4	-0.75	5.1e-02	ARFGAP2 DDB2 FNBP4 GPX1 MAPT UBA7 UBXN2A
Impedance of leg (left)	3.65	11	7	15.6	-0.15	6.4e-01	ERI1 FNBP4 FTSJ2 GPX1 MADD MVK RBM6 RNF123 STAG1 UBA7 UBXN2A
Leg pain on walking	3.64	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Diabetes (self-reported)	3.59	3	2	4.4	1.00	4.3e-03	MST1R RBM6 UBA7
Basal metabolic rate	3.58	9	6	13.3	0.53	9.4e-02	ARFGAP2 ERI1 GPX1 MST1R MVK RBM6 RNF123 UBA7 UBXN2A
Arm fat-free mass (right)	3.57	7	5	11.1	0.71	3.3e-02	ERI1 GPX1 MST1R RBM6 RNF123 UBA7 UBXN2A
Leg fat-free mass (left)	3.51	10	5	11.1	0.32	3.0e-01	ARFGAP2 ERI1 FNBP4 MST1R MVK PIGL RBM6 RNF123 UBA7 UBXN2A
Impedance of leg (right)	3.50	10	9	20.0	-0.04	9.0e-01	ERI1 FNBP4 GPX1 MADD MVK RBM6 RNF123 STAG1 UBA7 UBXN2A
Age started oral contraceptive pill	3.50	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Leg predicted mass (left)	3.49	10	5	11.1	0.25	4.6e-01	ARFGAP2 ERI1 FNBP4 MST1R MVK PIGL RBM6 RNF123 UBA7 UBXN2A
Forced expiratory volume in 1-second (FEV1)	3.49	6	3	6.7	-0.57	2.4e-01	ERI1 GPX1 MAPT RNF123 UBA7 UBXN2A
Hair/balding pattern: Pattern 4	3.49	1	1	2.2	0.00	1.0e+00	MAPT
Number of operations (self-reported)	3.47	2	0	0.0	0.00	1.0e+00	GPX1 RNF123
Diabetes diagnosed by doctor	3.45	3	1	2.2	1.00	4.4e-03	MST1R RBM6 UBA7
Irritable Bowel Disease (IBD)	3.40	4	4	8.9	-0.99	2.2e-04	GPX1 MST1R RBM6 UBA7
Type 2 Diabetes (T2D) (2018)	3.34	4	2	4.4	0.60	2.8e-01	FNBP4 MST1R RBM6 UBA7
Financial difficulties in last 2 years	3.33	1	0	0.0	0.00	1.0e+00	DRD2
Age when periods started (menarche)	3.30	4	3	6.7	1.00	5.0e-03	FNBP4 GPX1 MADD RNF123
Qualifications: NVQ or HND or HNC or equivalent	3.29	2	0	0.0	0.00	1.0e+00	MST1R RBM6
Prostate Cancer	3.28	1	0	0.0	0.00	1.0e+00	GPX1
Medication: Bendroflumethiazide	3.28	2	2	4.4	0.00	1.0e+00	ERI1 NR1H3
Number of live births	3.26	2	0	0.0	0.00	1.0e+00	MAPT RBM6
Qualifications: O levels/GCSEs or equivalent	3.25	1	1	2.2	0.00	1.0e+00	GPX1
Qualifications: nursing, teaching	3.25	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Forced vital capacity (FVC)	3.23	7	2	4.4	-0.77	4.3e-02	ARFGAP2 DDB2 FNBP4 GPX1 MAPT UBA7 UBXN2A
Medication for pain relief, constipation, heartburn	3.22	3	0	0.0	0.00	1.0e+00	GPX1 MAPT RP11-165J3.6
Medication: Blood pressure	3.21	2	1	2.2	0.00	1.0e+00	ERI1 NR1H3
Comparative body size at age 10	3.19	4	4	8.9	-1.00	1.1e-03	ERI1 FNBP4 MADD RP11-165J3.6
Medication: Seretide 50 evohaler	3.17	1	0	0.0	0.00	1.0e+00	UBA7
Ulcerative Colitis (UC)	3.15	4	2	4.4	-1.00	1.1e-03	GPX1 MST1R RBM6 UBA7
Medication: Metformin	3.15	2	1	2.2	0.00	1.0e+00	FNBP4 RBM6
Whole body water mass	3.15	11	6	13.3	0.26	4.1e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 GPX1 MST1R MVK RBM6 RNF123 UBA7 UBXN2A
Lung FVC	3.13	7	3	6.7	-0.90	5.5e-03	GPX1 MAPT PIGL RNF123 TCF4 UBA7 UBXN2A
Depression (self-reported)	3.13	1	0	0.0	0.00	1.0e+00	TMEM106B
Leg fat-free mass (right)	3.13	10	5	11.1	0.22	5.2e-01	ARFGAP2 ERI1 FNBP4 MST1R MVK PIGL RBM6 RNF123 UBA7 UBXN2A
Body Mass Index (BMI) (2010)	3.12	2	1	2.2	0.00	1.0e+00	FNBP4 MADD
Leg predicted mass (right)	3.12	10	5	11.1	0.21	5.3e-01	ARFGAP2 ERI1 FNBP4 MST1R MVK PIGL RBM6 RNF123 UBA7 UBXN2A
Whole body fat-free mass	3.10	10	6	13.3	0.16	6.4e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MST1R MVK RBM6 RNF123 UBA7 UBXN2A
Long-standing illness, disability or infirmity	3.06	1	0	0.0	0.00	1.0e+00	RBM6
Pulse rate, automated reading	3.05	5	4	8.9	0.29	5.7e-01	MST1R NR1H3 RBM6 RNF123 UBA7
Headache pain in last month	3.02	1	1	2.2	0.00	1.0e+00	MAPT
Blood White Count	3.00	8	6	13.3	0.53	1.2e-01	GPX1 MADD MAPT MST1R PIGL RBM6 UBA7 UBXN2A
Hair/balding pattern: Pattern 3	2.95	1	1	2.2	0.00	1.0e+00	MAPT
Ulcerative Colitis	2.94	3	1	2.2	0.00	1.0e+00	GPX1 RBM6 UBA7
Ever had bowel cancer screening	2.93	1	0	0.0	0.00	1.0e+00	UBA7
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.90	4	1	2.2	-0.99	6.5e-03	MAPT PIGL RNF123 UBA7
Father's age at death	2.87	1	0	0.0	0.00	1.0e+00	GPX1
Trunk fat-free mass	2.84	9	7	15.6	0.06	8.7e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MST1R RBM6 RNF123 UBA7 UBXN2A
Qualifications: CSEs or equivalent	2.82	1	0	0.0	0.00	1.0e+00	UBA7
Hand grip strength (left)	2.81	5	4	8.9	-0.20	7.5e-01	FNBP4 MADD MAPT TCF4 UBXN2A
Trunk predicted mass	2.79	9	6	13.3	0.05	8.8e-01	ARFGAP2 ARHGAP1 DDB2 ERI1 MST1R RBM6 RNF123 UBA7 UBXN2A
Seen a psychiatrist for nerves, anxiety, tension or depression	2.76	1	0	0.0	0.00	1.0e+00	TMEM106B
Neck or shoulder pain in last month	2.76	1	0	0.0	0.00	1.0e+00	GPX1
Medication: Ventolin 100micrograms inhaler	2.75	2	0	0.0	0.00	1.0e+00	MST1R RBM6
Mouth/teeth dental problems	2.73	1	0	0.0	0.00	1.0e+00	MVK
Stomach or abdominal pain in last month	2.65	1	0	0.0	0.00	1.0e+00	STAG1
Crohns Disease (2017)	2.60	4	2	4.4	-1.00	3.4e-03	GPX1 MST1R RBM6 UBA7
Relative age of first facial hair	2.59	2	1	2.2	0.00	1.0e+00	MAPT RNF123
Blood Red Count	2.58	7	4	8.9	0.51	2.4e-01	DRD2 MAPT MST1R RBM6 RNF123 UBA7 UBXN2A
Crohns Disease (2012)	2.56	3	0	0.0	0.00	1.0e+00	MST1R RBM6 UBA7
Medication: Blood pressure	2.56	3	0	0.0	0.00	1.0e+00	ERI1 MAPT NR1H3
High blood pressure (siblings)	2.55	1	0	0.0	0.00	1.0e+00	NR1H3
Sitting height	2.52	8	5	11.1	-0.54	1.7e-01	ARFGAP2 DDB2 ERI1 FNBP4 MADD MAPT PIGL UBXN2A
Smoking Status	2.48	3	2	4.4	0.00	1.0e+00	GPX1 MAPT RNF123
Peak expiratory flow (PEF)	2.48	2	2	4.4	0.00	1.0e+00	ERI1 MAPT
Cardiovascular Disease	2.47	2	1	2.2	0.00	1.0e+00	FTSJ2 NR1H3
Medication for cholesterol, blood pressure or diabetes	2.46	1	0	0.0	0.00	1.0e+00	UBA7
Current tobacco smoking	2.44	1	0	0.0	0.00	1.0e+00	UBXN2A
Schizophrenia (2014)	2.36	2	0	0.0	0.00	1.0e+00	DRD2 STAG1
Smoking status: Current	2.35	1	0	0.0	0.00	1.0e+00	UBXN2A
Respiratory disease	2.23	2	0	0.0	0.00	1.0e+00	MST1R RBM6
Asthma	2.22	1	0	0.0	0.00	1.0e+00	MST1R
Schizophrenia (2018)	2.21	1	0	0.0	0.00	1.0e+00	STAG1
Myopia	2.21	1	0	0.0	0.00	1.0e+00	FTSJ2
Medication: Ibuprofen (e.g. Nurofen)	2.19	2	0	0.0	0.00	1.0e+00	MAPT UBXN2A
Asthma (self-reported)	2.19	1	0	0.0	0.00	1.0e+00	MST1R
Pack years adult smoking proportion	2.17	1	0	0.0	0.00	1.0e+00	GPX1
Maternal smoking around birth	2.17	2	0	0.0	0.00	1.0e+00	RBM6 UBA7
Hand grip strength (right)	2.16	4	2	4.4	-0.17	8.3e-01	FNBP4 MADD MAPT TCF4
Breast Cancer	2.14	2	1	2.2	0.00	1.0e+00	MAPT NR1H3
Comparative height size at age 10	2.09	7	5	11.1	-0.73	6.1e-02	ARFGAP2 DDB2 GPX1 MAPT STAG1 TCF4 UBXN2A
Birth weight of first child	2.05	1	0	0.0	0.00	1.0e+00	PAFAH1B1
Average weekly champagne plus white wine intake	2.03	1	0	0.0	0.00	1.0e+00	MAPT
Relative age voice broke	2.01	1	1	2.2	0.00	1.0e+00	MAPT
Alzheimer’s Disease (including proxy)	1.99	1	0	0.0	0.00	1.0e+00	MADD
Chronotype (morning person)	1.95	1	0	0.0	0.00	1.0e+00	UBXN2A
Illnesses of father: High blood pressure	1.94	2	0	0.0	0.00	1.0e+00	MADD NR1H3
Pack years of smoking	1.94	1	0	0.0	0.00	1.0e+00	GPX1
Pulse rate	1.73	1	0	0.0	0.00	1.0e+00	RNF123
Ovarian Cancer	1.72	1	1	2.2	0.00	1.0e+00	MAPT
Waist Hip Ratio (WHR)	1.68	4	2	4.4	-0.29	7.1e-01	GPX1 MAPT STAG1 UBXN2A
Mouth/teeth dental problems: Mouth ulcers	1.68	1	1	2.2	0.00	1.0e+00	MAPT
Handedness (chirality/laterality): Left-handed	1.67	1	1	2.2	0.00	1.0e+00	MAPT
Standing height	1.64	13	7	15.6	-0.38	2.0e-01	ARFGAP2 DDB2 ERI1 FNBP4 FTSJ2 GPX1 MADD MAPT PAFAH1B1 RP11-165J3.6 STAG1 TMEM106B UBXN2A
Medication: Allopurinol	1.62	1	0	0.0	0.00	1.0e+00	PIGL
Blood Eosinophil Count	1.60	5	3	6.7	0.34	4.5e-01	GPX1 MAPT MST1R RBM6 UBA7
Hearing difficulty/problems: Yes	1.50	1	0	0.0	0.00	1.0e+00	MVK
Height	1.47	14	11	24.4	-0.48	8.0e-02	ARFGAP2 DDB2 FNBP4 FTSJ2 GPX1 MADD MAPT PAFAH1B1 RP11-165J3.6 RPA3 STAG1 TCF4 TMEM106B UBXN2A
Past tobacco smoking	1.46	1	0	0.0	0.00	1.0e+00	RNF123
Ever had prostate specific antigen (PSA) test	1.33	1	0	0.0	0.00	1.0e+00	PAFAH1B1
Lupus	1.29	1	0	0.0	0.00	1.0e+00	ERI1
Birth weight	1.15	1	0	0.0	0.00	1.0e+00	UBXN2A
Hypothyroidism/myxoedema (self-reported)	1.11	1	1	2.2	0.00	1.0e+00	ERI1
Medication: Levothyroxine sodium	1.02	1	0	0.0	0.00	1.0e+00	ERI1
Blood Platelet Count	0.82	4	3	6.7	-0.10	9.0e-01	ARFGAP2 FNBP4 MADD UBXN2A
Lung FEV1/FVC ratio	0.77	2	1	2.2	0.00	1.0e+00	MAPT RNF123
Hair Pigment	0.16	2	0	0.0	0.00	1.0e+00	ARFGAP2 DDB2

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Uterus	9	1.59	2.2
GTEx	Small Intestine Terminal Ileum	7	1.52	2.1
GTEx	Artery Coronary	13	1.10	2.0
GTEx	Brain Caudate basal ganglia	8	0.87	2.0
GTEx	Brain Cortex	13	1.26	2.0
GTEx	Brain Hypothalamus	4	0.68	2.0
GTEx	Colon Sigmoid	15	1.03	2.0
GTEx	Esophagus Gastroesophageal Junction	13	0.90	2.0
GTEx	Ovary	8	0.88	2.0
GTEx	Prostate	8	0.96	2.0
GTEx	Adipose Visceral Omentum	14	0.69	1.9
GTEx	Brain Frontal Cortex BA9	9	0.97	1.9
GTEx	Brain Putamen basal ganglia	5	0.80	1.9
GTEx	Heart Atrial Appendage	13	0.82	1.9
GTEx	Heart Left Ventricle	13	0.85	1.9
GTEx	Lung	22	0.77	1.9
GTEx	Pancreas	11	0.67	1.9
GTEx	Skin Not Sun Exposed Suprapubic	18	0.73	1.9
GTEx	Spleen	13	0.92	1.9
GTEx	Stomach	11	0.76	1.9
GTEx	Vagina	7	1.10	1.9
The Cancer Genome Atlas	Esophageal Carcinoma	3	0.44	1.9
GTEx	Adrenal Gland	8	0.55	1.8
GTEx	Artery Aorta	18	0.60	1.8
GTEx	Artery Tibial	15	0.40	1.8
GTEx	Brain Cerebellar Hemisphere	11	0.74	1.8
GTEx	Brain Cerebellum	12	0.61	1.8
GTEx	Brain Hippocampus	5	0.95	1.8
GTEx	Brain Nucleus accumbens basal ganglia	7	0.81	1.8
GTEx	Breast Mammary Tissue	13	0.66	1.8
GTEx	Breast Mammary Tissue (Female)	12	0.73	1.8
GTEx	Cells EBV-transformed lymphocytes	12	0.84	1.8
GTEx	Colon Transverse	14	0.68	1.8
GTEx	Esophagus Mucosa	16	0.48	1.8
GTEx	Esophagus Muscularis	20	0.62	1.8
GTEx	Liver	5	0.70	1.8
GTEx	Pituitary	7	0.63	1.8
GTEx	Skin Sun Exposed Lower leg	20	0.55	1.8
GTEx	Testis	17	0.54	1.8
GTEx	Thyroid	19	0.48	1.8
ROSMAP	Brain Pre-frontal Cortex	20	0.46	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	4	0.19	1.8
GTEx	Adipose Subcutaneous	16	0.46	1.7
GTEx	Cells Transformed fibroblasts	18	0.43	1.7
GTEx	Muscle Skeletal	9	0.31	1.7
GTEx	Nerve Tibial	18	0.42	1.7
GTEx	Whole Blood	9	0.45	1.7
NTR	Blood	9	0.37	1.7
CommonMind	Brain Pre-frontal Cortex	10	0.19	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	5	0.46	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	12	0.44	1.7
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	7	0.34	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	10	0.34	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	6	0.24	1.7
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	4	0.25	1.7
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	5	0.30	1.7
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	6	0.45	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	6	0.36	1.7
GTEx	Breast Mammary Tissue (Male)	6	0.50	1.6
METSIM	Adipose	7	0.15	1.6
YFS	Blood	5	0.11	1.6
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	6	0.36	1.6
The Cancer Genome Atlas	Breast Invasive Carcinoma	9	0.20	1.6
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.29	1.6
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	13	0.32	1.6
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.28	1.6
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	4	0.36	1.6
The Cancer Genome Atlas	Prostate Adenocarcinoma	10	0.22	1.6
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	1.6
The Cancer Genome Atlas	Soft Tissue Sarcoma	2	0.19	1.6
The Cancer Genome Atlas	Thyroid Carcinoma	8	0.16	1.6
The Cancer Genome Atlas	Testicular Germ Cell Tumors	3	0.23	1.5
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.4
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	1.4